CTLA-4

CTLA-4
Name	Cytotoxic T-lymphocyte-associated protein 4
Uniprot	P16410
Organism	Homo sapiens

CTLA-4 is an immune checkpoint receptor expressed on activated T cell subsets and regulatory T cells that modulates adaptive immune responses. Discovered in the context of co-stimulatory biology alongside CD28 and B7 ligands, it acts as a critical brake on T cell activation, maintaining self-tolerance and limiting immunopathology. Studies spanning institutions such as the National Institutes of Health, Harvard University, and the Pasteur Institute have elucidated its structural features, intracellular trafficking, and therapeutic potential.

Structure and expression

CTLA-4 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily, with an extracellular V-set domain, a transmembrane helix, and a short cytoplasmic tail containing motifs critical for endocytosis and signaling. Structural determination employed methods developed at European Molecular Biology Laboratory and Max Planck Institute cryo-crystallography facilities and built on paradigms set by Rosalind Franklin-era macromolecular techniques. The receptor’s extracellular region binds the ligands CD80 and CD86, which were characterized in parallel by groups at Stanford University and the University of Cambridge. Expression is inducible on effector CD4+ T cell and CD8+ T cell populations and constitutive on thymically derived Treg cells; expression kinetics were profiled in cohorts from Johns Hopkins University and clinical centers like Mayo Clinic.

Mechanism of action

CTLA-4 competes with CD28 for shared ligands CD80 and CD86, engaging in higher-avidity interactions that reduce co-stimulatory signaling through PI3K and AKT pathways described by laboratories at Massachusetts Institute of Technology and University of California, San Francisco. The cytoplasmic tail contains motifs recognized by adaptor proteins such as AP-2 and signaling enzymes including SHP2 and PP2A, regulating receptor internalization and phosphatase recruitment; these molecular interactions were dissected in studies affiliated with Cold Spring Harbor Laboratory and Scripps Research. CTLA-4 also mediates trans-endocytosis of ligand from antigen-presenting cells characterized in collaborations involving University College London and the Wellcome Trust. These mechanisms converge to diminish T cell receptor (TCR) signaling cascades previously mapped in work from Rockefeller University.

Role in immune regulation and tolerance

CTLA-4 is central to maintaining peripheral tolerance and preventing autoimmunity in murine models and human cohorts studied at European Molecular Biology Laboratory-affiliated centers and hospital systems like Charité – Universitätsmedizin Berlin. Loss-of-function experiments performed at University of Cambridge and the Max Planck Institute of Immunobiology demonstrated fatal lymphoproliferative syndromes, while clinical descriptions from Addenbrooke's Hospital and Great Ormond Street Hospital documented autoimmune manifestations associated with defective checkpoint control. CTLA-4 is essential for Treg suppressive function in settings such as transplantation studied at Mayo Clinic and graft-versus-host disease models at Fred Hutchinson Cancer Research Center, and it participates in shaping tolerogenic responses during infections reported by teams at Institut Pasteur and University of Oxford.

Clinical significance and therapeutic targeting

CTLA-4 blockade with monoclonal antibodies inaugurated the field of immune checkpoint therapy through clinical trials conducted at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute, leading to approvals by regulatory bodies including the Food and Drug Administration for agents tested in melanoma cohorts from University of California, Los Angeles. Antagonists such as ipilimumab altered cancer care paradigms described in reports from MD Anderson Cancer Center and the European Society for Medical Oncology, while agonists and recombinant fusion proteins like CTLA-4–Ig (abatacept) are used to treat autoimmune diseases in trials run by Roche and Bristol-Myers Squibb collaborations and in rheumatology centers such as Hospital for Special Surgery. Adverse effects including immune-related adverse events were cataloged by consortia involving National Cancer Institute and European Medicines Agency investigators.

Genetic variants and disease associations

Polymorphisms in the CTLA4 locus were linked to susceptibility loci identified in genome-wide association studies coordinated by consortia including Wellcome Trust Case Control Consortium and research groups at University of Oxford and Harvard Medical School. Variants have been associated with autoimmune conditions characterized at specialist centers—such as Type 1 diabetes cohorts at Karolinska Institutet, Graves' disease studies at University of Tokyo, and Rheumatoid arthritis registries at University College London—and with transplant outcomes monitored at Cleveland Clinic. Rare mutations causing CTLA-4 haploinsufficiency were defined by clinical genetics teams at Great Ormond Street Hospital and King's College London.

Experimental models and assays

Mouse knockout and conditional models developed at The Jackson Laboratory and EMBL remain foundational for dissecting CTLA-4 biology, while humanized mouse systems were deployed by groups at Yale University and University of Pennsylvania. In vitro assays include ligand-binding studies using recombinant CD80/CD86 produced in cores affiliated with European Bioinformatics Institute and flow cytometry panels standardized across networks including International Society for Advancement of Cytometry. Functional readouts utilize T cell proliferation assays traced to methodology from Stanford University and immunohistochemical localization techniques refined at Memorial Sloan Kettering Cancer Center.

Category:Immune checkpoint proteins